EASTGATE BIOTECH RECEIVES NOTICE OF PUBLICATION FROM THE US PATENT AND TRADEMARK OFFICE FOR TWO PATENTS FOR THE COMPANY’S PROPRIETARY INTRAORAL LORAZEPAM SPRAY
WEST CALDWELL, NJ and TORONTO, ON–(Marketwired – January 19, 2016) – EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received the notice of publication from the US Patent and Trademark Office for two patents for the company’s intraoral Lorazepam Spray.
The details of the notice of publications are as follows:
Following patent applications published under publication numbers:
US2016/0000702 PHARMACEUTICAL COMPOSITION FOR ENHANCED TRANSMUCOSAL ADMINSTRATION OF BENZODIAZEPINES
US2016/0000803 PHARMACEUTICAL COMPOSITION FOR TRANSMUCOSAL ADMINISTRATION OF BENZODIAZEPINES
The intraoral Lorazepam Spray is a non-invasive solution for the treatment of acute and repetitive seizures. This spray is a low volume, oral anti-convulsant formulation designed to be a quick and effective treatment of acute seizures in hospital, home or ambulatory settings. This delivery form of the most potent anticonvulsant is an exceptionally convenient alternative to injectable benzodiazepines that efficiently control epileptic emergencies. The intraoral oral spray formulation can be used by the patient, paramedics, or any other available non-trained persons, even during on ongoing seizure.
“We look forward to progressing with this key pharmaceutical development with these patent publications leading the way” says Anna Gluskin, EastGate’s CEO. “Lorazepam oral spray, based on our proprietary delivery technology, can be groundbreaking in the anti-seizure market where a fast and effective treatment can be applied by any patient or caregiver resulting in a positive therapeutic impact” continues Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Rose Perri 1-647-692-0652